Mesenchymal stem cells (MSCs) are gaining importance among clinicians following recent demonstration of safe allogeneic transplantation due to their ability to modulate the immune response. However, the molecular machinery regulating the expression of immunomodulatory factors in MSCs is unknown. We, therefore, inhibited glycogen synthase kinase-3 (GSK-3), a Wnt signaling inhibitor, to elucidate the role of Wnt signaling in mediating immunoregulatory effects of human MSCs using gene expression profiling. Our results highlight enhanced ability of GSK-3 inhibitor (lithium) treated MSCs to evade immune response as a result of decreased expression of immune stimulatory cytokines and chemokines.
Mesenchymal stem cells isolated from bone marrow cells are capable of in vitro expansion and have been demonstrated to differentiate not only into osteoblast, chondrocyte, adipocyte, fibroblast, tendenocyte and myoblast but undergo transdifferentiation into cardiomyocyte, hepatocyte, neuronal and endothelial cells in vitro (Satija et al, 2009) . Their pluripotent character (depicted in comparison to other stem cells, Figure 1 ), lack of expression of MHC-II molecules (Le Blanc et al, 2003) and recently studies documenting clinical safety (Koc et al, 2002) have brought MSCs to the forefront in the field of regenerative medicine.
MSCs being present in the bone marrow have been identified to constitute part of hematopoietic niche and influence hematopoietic stem cell (HSC) fate (Mendez-Ferrer et al, 2010) . Apart from direct cell-cell contact, MSCs secrete a variety of growth factors and cytokines known to regulate HSC, their progeny and modulate immune cell function (Majumdar et al, 2000; Pedemonte et al, 2007) . However, hypoimmunogenecity of MSCs attributed to lack of MHC class-II and costimulatory molecules (CD40, CD80 and CD86) (Le Blanc et al, 2003; Majumdar et al, 2003) led to testing them in allogeneic situations and were reported to evade rejection (Ryan et al, 2005) . Not only restricted to their ability to avoid allogeneic rejection, they are also capable of suppressing the immune response and therefore have been assessed in clinical trials for graft-versus-host disease but with inconsistent outcome (Lazarus et al, 2005; Le Blanc et al, 2008) .
Studies have been performed to evaluate the molecular basis of MSC-mediated immune suppression. Since Wnt signaling plays a significant role in regulating MSC function (Luo et al, 2007) , we performed gene expression profiling to evaluate the effect of GSK-3, a negative regulator of Wnt signaling, inhibition in human MSCs on the expression of genes involved in immune response modulation. Early passage (p2-4) hMSCs from 3 donors were subjected to lithium chloride, a GSK-3 inhibitor, treatment for 7 days and microarray-based expression profiling was performed using Agilent Whole genome oligonucleotide array (4x44k format). Data normalization was done using GeneSpring GX 11 and ratios (log 2 transformed) were computed for each donor. Genes showing atleast 20% change in expression in all the donors were considered for further analysis and those involved in immune response were selected based on GeneOntology classification.
Gene expression profiling of lithium stimulated human MSCs reveals role of GSK-3 in regulating levels of immune-regulatory molecules. Inhibition of GSK-3 leads to a decrease in the synthesis of various cytokines and chemokines implicated in chemotaxis and activation of immune cells (Table 1) . For instance, IL8, a chemotactic and activation factor for neutrophils, and thus involved in inflammatory responses was found to be downregulated. CXCL12, also known as stromal derived factor-1, implicated to play role in HSC homing to bone marrow (Sharma et al, 2010) , acts as a strong chemoattractant for T-lymphocytes and monocytes. Its downregulation in hMSCs following lithium treatment is in agreement with study of de Boer et al (de Boer et al, 2004) . The expression of other chemokines like CXCL1, CXCL2 and CCL20, which acts as attractant for lynphocytes, monocytes and neutrophils, is repressed and highlights reduced immunogenic response of MSCs. CXCL2 and IL7 downregulation observed in our study is supported by recent study using BIO (a GSK-3 inhibitor) treated human MSCs (Krause et al, 2010) .
Our data also demonstrated significant downregulation of interleukin-8 and co-stimulatory molecule CD86 involved in alloreactive T-cell activation (Aggarwal & Pittenger, 2005) . However, the effect of upregulated expression of CD70, which stimulates T-cell activation, on MSC immune response needs to be evaluated since MSCs express low MHC class-I and no MHC class-II molecules. We further found downregulation of IL6 (involved in lymphocyte and monocyte differentiation) and IL1A (involved in inflammatory response) but the results were not statistically significant. Moreover, lithium treatment does not affect the expression levels of MHC class-I molecules (HLA-A,-B,-C,-E,-F,-H), though the effect on MHC class-II is inconsistent among the donors. Expression of indoleamine 2,3-dioxygenase (IDO), which catabolises L-Tryptophan resulting in inhibition of allogeneic T-cell responses, was also observed to be upregulated (1.9 fold) but not statistically significant (Meisel et al, 2004) . Increased expression of IDO is of significance since it helps in creating a local immune-suppressive milieu. Thus, overall these preliminary results bring to light the importance of Wnt/GSK-3 signaling in immunomodulatory function of hMSCs and greater hypoimmunogenic character of lithium-stimulated MSCs. 
